SBC Medical loses Nasdaq compliance after director departure; cure period granted

SBC Medical Group Holdings Inc

Director Mike Sayama did not seek re-election, leaving board with 2 of 4 independent directors and audit committee with 2 members.
Nasdaq granted cure period until earlier of next annual meeting or July 9, 2027; company searching for a fifth independent director.
Shareholders approved charter amendments: eliminate plurality voting, remove for-cause removal, opt out of DGCL Section 203, and officer exculpation.
Bylaws amended to incorporate universal proxy rules, update quorum, and enhance advance notice provisions for stockholder nominations.
All four director nominees elected with over 90 million votes each; ratification of auditor MaloneBailey approved.

item 3.01 item 3.03 item 5.03 item 5.07 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.